<DOC>
	<DOCNO>NCT00634231</DOCNO>
	<brief_summary>This study evaluate administration AdV-tk follow valacyclovir child malignant glioma , include glioblastoma multiforme ( GBM ) anaplastic astrocytoma ( AA ) , well recurrent ependymomas combination radiation therapy . The primary objective determine approach safe effectively deliver without disturb standard therapy .</brief_summary>
	<brief_title>A Phase I Study AdV-tk + Prodrug Therapy Combination With Radiation Therapy Pediatric Brain Tumors</brief_title>
	<detailed_description>This Open label , Phase I , dose escalation study . Patients receive injection AdV-tk tumor tumor bed surgical procedure follow 14 day anti-herpetic prodrug , valacyclovir , start 1-3 day vector injection . Standard radiotherapy begin 3-7 day AdV-tK injection . Standard chemotherapy may begin completion valacyclovir discretion treat physician family . Two dose level AdV-tk evaluate fix dose valacyclovir .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<criteria>Patients must 3 year age old Patients must plan undergo standard care treatment surgery radiation therapy . Patients must malignant glioma recurrent ependymoma Tumor must accessible injection must locate brainstem deep midbrain Performance Score : Karnofsky ≥60 % &gt; 10y/o , Lansky ≥60 ≤10y/o Bone Marrow Function : Patients must adequate bone marrow function define peripheral absolute neutrophil count ≥ 1000/µl , platelet count ≥ 100,000/µl ( transfusion independent ) hemoglobin ≥ 8.0 gm/dL Renal Function : Patients must serum creatinine ≤ 1.5 time upper limit institutional normal age and/or GFR ≥ 70 mL/min/1.73 m2 . Hepatic Function : Bilirubin ≤ 1.5 time institutional normal ; SGPT ( ALT ) &lt; 3 time institutional normal Serum electrolyte value ( sodium , potassium , magnesium , calcium ) must check prior enrollment clinically significant abnormality correct prior surgery/AdVtk injection Patients seizure disorder may enrol well control Signed inform consent accord institutional guideline must obtain Prior ongoing liver disease include known cirrhosis , hepatitis B C infection exclude patient distant history resolve hepatitis A infection Patients immunosuppressive drug ( exception corticosteroid ) Known history HIV underlying immunodeficiency Patients acute infection ( viral , bacterial fungal infection require therapy ) Pregnant breastfeed patient . Female patient childbearing age must negative serum urine pregnancy test within 1 week begin therapy Other serious comorbid illness compromise organ function No investigational antitumor agent within 30 day prior study entry active participation study ( define study entry tumor progression )</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Malignant glioma</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Anaplastic astrocytoma</keyword>
	<keyword>Recurrent ependymoma</keyword>
	<keyword>Gene therapy</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>